During the past decade, CRS Clinical Research Services Wuppertal GmbH conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "CRS Clinical Research Services Wuppertal GmbH" are "Healthy Volunteer" (1 trials), "Healthy Volunteers" (1 trials), "Hot Flashes" (1 trials) and "Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men" (1 trials). Many other conditions were trialed in "CRS Clinical Research Services Wuppertal GmbH" in a lesser frequency.

Most popular intervention types in "CRS Clinical Research Services Wuppertal GmbH" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "BAY1101042" (1 trials), "Dabigatran etexilate" (1 trials), "Elinzanetant (BAY3427080)" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "CRS Clinical Research Services Wuppertal GmbH" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CRS Clinical Research Services Wuppertal GmbH". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in CRS Clinical Research Services Wuppertal GmbH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CRS Clinical Research Services Wuppertal GmbH, 2 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".